Non-Vegetarian Ingredient In Herbal Tooth Powder, Delhi HC Issues Notice To Patanjali Ayurveda And Baba Ramdev

New Delhi: Patanjali Ayurved Limited, led by yoga guru Ramdev, is once again under legal scrutiny as the Delhi high court has demanded responses from the Centre, the Food Safety and Standards Authority of India (FSSAI), and the company over a petition alleging misbranding of its “Divya Dant Manjan” dental care product.

The petition, filed by lawyer Yatin Sharma, claims that despite “Divya Dant Manjan” being marketed with a green dot — an indicator of vegetarian status — it actually contains “samudraphen,” a fish-derived compound.

This, according to Sharma, constitutes “misbranding” under the Drugs and Cosmetics Act. Although the law does not mandate specific labelling for drugs as vegetarian or non-vegetarian, the use of the green dot qualifies as “misbranding” under the Drugs and Cosmetics Act, the petitioner’s counsel argued.

Justice Sanjeev Narula issued notice to the Centre, the FSSAI as well as Patanjali, Divya Pharmacy, Yoga guru Ramdev and other related parties on Sharma’s petition.

The petitioner, represented by advocates Swapnil Chaudhary and Prashant Gupta, said the discovery was “distressing” for him and his family, particularly because they adhere to a strict vegetarian diet due to religious beliefs.

“Respondent No. 3 (Patanjali Ayurveda) is selling the same product with a green dot on their official website, indicating that the product is vegetarian in nature, which is contradictory.

“The Petitioner seeks redressal for the profound distress caused by the inadvertent consumption of a non-vegetarian product, emphasizing the importance of upholding religious beliefs and ensuring transparency in product representation,” the petition, filed through lawyers Mohit Solanki and Pulkit Chaudhary, stated.

The matter would be heard next in November.

Related Posts

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?